Superficial Vein ThrombosisSUPERCATNCT07210671
Prospective Evaluation of the Treatment of Cancer Associated Superficial Venous
An observational study of Superficial Vein Thrombosis and Cancer, run by Centre Hospitalier Universitaire, Amiens at 1 site in France.
Trial summary
Superficial venous thrombosis (SVT) is very common in clinical practice. What's more, around 15- 20% of SVTs occur in the context of cancer. Today, cancer patients are excluded from therapeutic trials for DVT. There is therefore no high-level evidence-based treatment recommendation for these patients. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Superficial Vein Thrombosis, Cancer, Venous Thrombosis
- How many people
- 1,576 participants
- Where
- 1 siteFrance
- Study dates
- 10 Nov 2025to Nov 2028
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patient with active cancer: * Cancer treatment within the last 6 months, * Detectable tumor disease, cancer treatment within the last 6 months, ongoing hormone therapy for cancer, palliative cancer. * The patient has received potentially non-curative cancer treatment (notably palliative chemotherapy). * Progression shows that the cancer treatment was not curative (due to recurrence or progression under treatment) (particularly in the case of recurrence after surgery)
Who may be able to join
- Patient over 18
- Patient affiliated to a social security scheme
- Patient who understands French
- Patient with superficial venous thrombosis of the lower and upper limbs confirmed by a Doppler ultrasound less than one month old.
- Patient with active cancer:
- Cancer treatment within the last 6 months,
Show all 9Show fewer
- Detectable tumor disease, cancer treatment within the last 6 months, ongoing hormone therapy for cancer, palliative cancer.
- The patient has received potentially non-curative cancer treatment (notably palliative chemotherapy).
- Progression shows that the cancer treatment was not curative (due to recurrence or progression under treatment) (particularly in the case of recurrence after surgery)
Who cannot join
- Patients under legal protection
- Patients with concomitant pulmonary embolism
- Patient with proximal or distal deep vein thrombosis
- Patient treated with anticoagulant therapy for another indication
- Patient with a contraindication to anticoagulation: Thrombocytopenia less than 30,000 elements/mm3, active bleeding or history of severe bleeding.
- Patient opposed to participation in research
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site, 1 recruiting
- Recruiting
CHU Amiens
Amiens, 80480
SOUDET Simon, MD, 03 22 88 72 89, soudet.simon@chu-amiens.fr
Laurent Bertoletti, MD
About this study
Superficial venous thrombosis (SVT) is very common in clinical practice. What's more, around 15- 20% of SVTs occur in the context of cancer. Today, cancer patients are excluded from therapeutic trials for DVT. There is therefore no high-level evidence-based treatment recommendation for these patients. Recent data suggest that the course of cancer-associated DVT is similar to that of cancer-associated deep vein thrombosis (DVT). However, there are currently few prospective data on the evolution of cancer-associated DVT in relation to the treatment used. Due to the absence of clear recommendations of treatment in case of SVT associated with cancer the investigators will perform a prospective observational study to evaluate the efficacy of different regiment of anticoagulant treatment ordered in clinical practice.
- Conditions
- Superficial Vein Thrombosis, Cancer, Venous Thrombosis
- Keywords
- Superficial vein thrombosis, cancer, venous thrombosis
- Medical subject headings
- Neoplasms, Venous Thrombosis
What is being measured
The primary outcome is the main question the study is designed to answer.
risk (in %) of recurrence of VTE
risk of recurrence of VTE at 3-month follow-up in patients with cancer-associated SVT.
Measured: at 3-month follow-up
Secondary outcomes (19)
association (%) between initial treatment and the risk of SVT recurrence
Measured: at 3 months
association (%) between initial treatment and the risk of SVT recurrence
Measured: at 6 months
association (%) between initial treatment and the risk of SVT recurrence
Measured: at 12 months
Association (%) between initial treatment and the occurrence of pulmonary embolism (PE)
Measured: at 12 months
Association (%) between initial treatment and the occurrence of pulmonary embolism (PE)
Measured: at 3 months
Association (%) between initial treatment and the occurrence of DVT
Measured: at 3 months
Association (%) between initial treatment and the occurrence of pulmonary embolism (PE)
Measured: at 6 months
Association (%) between initial treatment and the occurrence of DVT
Measured: at 12 months
Association (%) between initial treatment and the occurrence of DVT
Measured: at 6 months
association (%) between initial treatment and bleeding events
Measured: at 6 months
association (%) between initial treatment and bleeding events
Measured: at 3 months
association (%) between initial treatment and bleeding events
Measured: at 12 months
association(%) between initial treatment and all-cause death
Measured: at 3 months
association(%) between initial treatment and all-cause death
Measured: at 6 months
association(%) between initial treatment and all-cause death
Measured: at 12 months
rates of recurrence of symptomatic vs. incidental VTE
Measured: at 3 months
rates of recurrence of symptomatic vs. incidental VTE
Measured: at 6 months
rates of recurrence of symptomatic vs. incidental VTE
Measured: at 12 months
rate of confirmed cancer in patients with TVS suspected of having cancer.
Measured: at 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Oct 2025
- Study start10 Nov 2025
- Primary completionNov 2027 (estimated)
- Study completionNov 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Superficial Vein ThrombosisStudies of the same condition, open and under way.
- More trials run by Centre Hospitalier Universitaire, AmiensThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 1,576 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Centre Hospitalier Universitaire, Amiens
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07210671
- Sponsor's protocol ID
- PI2024_843_0121
- Acronym
- SUPERCAT
- Status last verified
- Apr 2026
- First submitted
- 30 Sep 2025
- Last updated
- 14 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 14 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prospective Evaluation of the Treatment of Cancer Associated Superficial Venous
- ClinicalTrials.gov ID
- NCT07210671
- Acronym / sponsor ID
- SUPERCAT / PI2024_843_0121
- Conditions
- Superficial Vein Thrombosis, Cancer, Venous Thrombosis
- Keywords
- Superficial vein thrombosis, cancer, venous thrombosis
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 1,576 participants (estimated)
- Lead sponsor
- Centre Hospitalier Universitaire, AmiensUniversity, hospital or other
- Study start
- 10 Nov 2025 (actual)
- Primary completion
- Nov 2027 (estimated)
- Study completion
- Nov 2028 (estimated)
- First posted
- 7 Oct 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Superficial venous thrombosis (SVT) is very common in clinical practice. What's more, around 15- 20% of SVTs occur in the context of cancer. Today, cancer patients are excluded from therapeutic trials for DVT. There is therefore no high-level evidence-based treatment recommendation for these patients. Recent data suggest that the course of cancer-associated DVT is similar to that of cancer-associated deep vein thrombosis (DVT). However, there are currently few prospective data on the evolution of cancer-associated DVT in relation to the treatment used. Due to the absence of clear recommendations of treatment in case of SVT associated with cancer the investigators will perform a prospective observational study to evaluate the efficacy of different regiment of anticoagulant treatment ordered in clinical practice.
Study design
- Observational model
- Case only
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patient with active cancer: * Cancer treatment within the last 6 months, * Detectable tumor disease, cancer treatment within the last 6 months, ongoing hormone therapy for cancer, palliative cancer. * The patient has received potentially non-curative cancer treatment (notably palliative chemotherapy). * Progression shows that the cancer treatment was not curative (due to recurrence or progression under treatment) (particularly in the case of recurrence after surgery)
Key inclusion criteria (9 listed)
- Patient over 18
- Patient affiliated to a social security scheme
- Patient who understands French
- Patient with superficial venous thrombosis of the lower and upper limbs confirmed by a Doppler ultrasound less than one month old.
- Patient with active cancer:
Key exclusion criteria (6 listed)
- Patients under legal protection
- Patients with concomitant pulmonary embolism
- Patient with proximal or distal deep vein thrombosis
- Patient treated with anticoagulant therapy for another indication
- Patient with a contraindication to anticoagulation: Thrombocytopenia less than 30,000 elements/mm3, active bleeding or history of severe bleeding.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
risk (in %) of recurrence of VTE
Time frame: at 3-month follow-up
risk of recurrence of VTE at 3-month follow-up in patients with cancer-associated SVT.
19 secondary outcomes
association (%) between initial treatment and the risk of SVT recurrence
Time frame: at 3 months
association (%) between initial treatment and the risk of SVT recurrence
Time frame: at 6 months
association (%) between initial treatment and the risk of SVT recurrence
Time frame: at 12 months
Association (%) between initial treatment and the occurrence of pulmonary embolism (PE)
Time frame: at 12 months
Association (%) between initial treatment and the occurrence of pulmonary embolism (PE)
Time frame: at 3 months
Association (%) between initial treatment and the occurrence of DVT
Time frame: at 3 months
Association (%) between initial treatment and the occurrence of pulmonary embolism (PE)
Time frame: at 6 months
Association (%) between initial treatment and the occurrence of DVT
Time frame: at 12 months
Association (%) between initial treatment and the occurrence of DVT
Time frame: at 6 months
association (%) between initial treatment and bleeding events
Time frame: at 6 months
association (%) between initial treatment and bleeding events
Time frame: at 3 months
association (%) between initial treatment and bleeding events
Time frame: at 12 months
association(%) between initial treatment and all-cause death
Time frame: at 3 months
association(%) between initial treatment and all-cause death
Time frame: at 6 months
association(%) between initial treatment and all-cause death
Time frame: at 12 months
rates of recurrence of symptomatic vs. incidental VTE
Time frame: at 3 months
rates of recurrence of symptomatic vs. incidental VTE
Time frame: at 6 months
rates of recurrence of symptomatic vs. incidental VTE
Time frame: at 12 months
rate of confirmed cancer in patients with TVS suspected of having cancer.
Time frame: at 12 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Apr 2026.
- Individual participant dataSharing planned: No
Related trials for Superficial Vein Thrombosis
Not yet recruitingObservational study
Superficial Vein Thrombosis Testing in the Emergency Department
Superficial Vein Thrombosis, D-dimer
Not yet recruitingPhase 2
Acetylsalicylic Acid Versus Placebo as an add-on Treatment to Local Non-steroidal Anti-inflammatory Drug for the Management of Thrombotic Episodes in Superficial Venous Malformations in Children Aged 6 to 17 Years.
Venous Malformation, Low Flow, Venous Malformations
Recruiting
Superficial Vein Thrombosis of the Upper Limb in Bacteremia Associated With PICCline and Midline Catheters: Frequency and Clinical Consequences
Catheter Associated Infection
RecruitingPhase 4
THRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE)
Venous Thromboembolism, Varicose Veins
Active, not recruiting
Chronic Venous Thrombosis: Relief With Adjunctive Catheter-Directed Therapy (The C-TRACT Trial)
Deep Vein Thrombosis, Venous Stasis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Superficial Vein Thrombosis and Cancer, run by Centre Hospitalier Universitaire, Amiens at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 14 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Simon SOUDET, Dr (33+3 22 08 80 51, soudet.simon@chu-amiens.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
risk (in %) of recurrence of VTE (time frame: at 3-month follow-up). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Apr 2026.